Hunan Er Kang Pharmaceutical (300267) — Working Capital to Net Assets Ratio
Hunan Er Kang Pharmaceutical (300267) has a Working Capital to Net Assets ratio of 24.5% as of June 2025. Working capital of CN¥1.08 Billion (current assets of CN¥1.62 Billion minus current liabilities of CN¥533.87 Million) is measured against net assets of CN¥4.42 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hunan Er Kang Pharmaceutical (300267) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hunan Er Kang Pharmaceutical Working Capital to Net Assets (2016–2024)
This chart shows how Hunan Er Kang Pharmaceutical's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the ratio stands at 24.5%, reflecting working capital of CN¥1.08 Billion against net assets of CN¥4.42 Billion CNY. Check 300267 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hunan Er Kang Pharmaceutical (2016–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hunan Er Kang Pharmaceutical from 2016 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Hunan Er Kang Pharmaceutical (300267) market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 23.0% | CN¥1.01 Billion | CN¥4.40 Billion | CN¥1.72 Billion | CN¥705.34 Million | ▼ -0.5 pp |
| 2023 | 23.4% | CN¥1.13 Billion | CN¥4.81 Billion | CN¥1.73 Billion | CN¥603.30 Million | ▼ -3.6 pp |
| 2022 | 27.0% | CN¥1.37 Billion | CN¥5.05 Billion | CN¥2.09 Billion | CN¥725.43 Million | ▼ -2.7 pp |
| 2021 | 29.7% | CN¥1.45 Billion | CN¥4.87 Billion | CN¥1.95 Billion | CN¥498.93 Million | ▼ -4.5 pp |
| 2020 | 34.2% | CN¥1.98 Billion | CN¥5.79 Billion | CN¥2.68 Billion | CN¥691.51 Million | ▼ -8.6 pp |
| 2019 | 42.9% | CN¥2.48 Billion | CN¥5.79 Billion | CN¥2.75 Billion | CN¥269.99 Million | ▼ -6.4 pp |
| 2018 | 49.3% | CN¥2.78 Billion | CN¥5.64 Billion | CN¥3.06 Billion | CN¥279.14 Million | ▲ +3.5 pp |
| 2017 | 45.8% | CN¥2.48 Billion | CN¥5.41 Billion | CN¥2.73 Billion | CN¥244.76 Million | ▲ +9.6 pp |
| 2016 | 36.3% | CN¥1.90 Billion | CN¥5.24 Billion | CN¥2.25 Billion | CN¥350.10 Million | — |